KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel ...

The company had blamed FDA "resource constraints" for the delay, while a rival drug for hereditary angioedema received an ...

FDA approval of EKTERLY makes KalVista Pharmaceuticals, Inc. the first to offer an oral on-demand HAE therapy. Click here to find out why KALV is a Strong Buy.

There's a clear downside to the Norwegian policy that encourages allowing elderly people to live at home for as long as ...

E-bike battery malfunction leads to fire and first NYC battery-related death in 2025, trapping 76-year-old woman in a Queens pizzeria.